MediWound (Nasdaq: MDWD) is a biotechnology niche specialty company focused on developing, manufacturing and globally commercializing innovative products that address unmet needs in the fields of severe burn and chronic wound management.

MediWound’s lead product, NexoBrid^TM, successfully completed clinical development in hospitalized burn wounds and is commercialized throughout Europe.

MediWound’s second innovative product candidate, EscharEx^®, currently in advanced clinical trials, is being developed for debridement of chronic and other hard-to-heal wounds.